Log In
Print
BCIQ
Print
Print this Print this
 

Quillivant XR, methylphenidate (NWP06)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionMethylphenidate extended-release oral suspension
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat attention deficit hyperactivity disorder (ADHD)
Regulatory Designation

Partner

Tris Pharma Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$680.0M

$255.0M

$425.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today